- Home
- LPCN
LPCN
Lipocine Inc.
as 04-23-2025 4:00pm EST
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 16.1M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 10.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.75 - $11.79 | Next Earning Date: | 05-08-2025 |
| Revenue: | $11,198,144 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -86.3% | Revenue Growth (next year): | -32.20% |
Latest Lipocine Inc. News
LPCN Breaking Stock News: Dive into LPCN Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
a month ago
Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression
PR Newswire
a month ago
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
PR Newswire
a month ago
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024
PR Newswire
a month ago
Lipocine Announces FDA Labeling Changes for Testosterone Products
PR Newswire
3 months ago
Lipocine Receives Updated Regulatory Guidance on LPCN 1154
MT Newswires
4 months ago
Sector Update: Health Care
MT Newswires
4 months ago
Lipocine Says LPCN 1148 Gets FDA Fast Track Label
PR Newswire
4 months ago
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
Compare LPCN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LPCN Lipocine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.